BioAtla (United States)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 9 of 9 papers

  • Research Article

Abstract 2693: BA3361, a tumor selective, conditionally active biologic (CAB) anti-nectin4-ADC with a novel NextGen linker system enhances therapeutic efficacy in pancreatic cancer

  • Apr 21, 2025
  • Cancer Research
  • Jing Wang +6
  • Research Article

Abstract 6335: Developing anti-IL-22 therapeutics for inflammation and cancer

  • Apr 04, 2023
  • Cancer Research
  • Christina Wheeler +10
  • Research Article
  • Citations4

Abstract B022: Targeting senescence cells in cancer and aging by conditionally active biologic therapeutics

  • Jan 15, 2023
  • Cancer Research
  • Jian Chen +10
  • Open Access
  • Research Article

BİR BALKAN NEOKLASİK TÜRK ŞAİRİNİN ESERLERİ HAKKINDA BİR TANITIM

  • Jan 01, 2023
  • BALKAN TÜRKOLOJİ ARAŞTIRMALARI MERKEZİ
  • Tacida Hafiz
  • Research Article
  • Citations1

Abstract 1870: Novel conditionally active bispecific T cell engagers targeting solid tumors

  • Jul 01, 2021
  • Cancer Research
  • Haizhen Liu +9
  • Open Access
  • Research Article
  • Citations44

Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches

  • Feb 24, 2021
  • Proceedings of the National Academy of Sciences of the United States of America
  • Hwai Wen Chang +6
  • Research Article
  • Citations1

Abstract 356: Novel conditionally active biologic (CAB) antibody targeting EpCAM demonstrates anti-tumor efficacy in vivo

  • Jul 01, 2019
  • Cancer Research
  • Cathy Chang +9
  • Conference Article

Abstract 356: Novel conditionally active biologic (CAB) antibody targeting EpCAM demonstrates anti-tumor efficacy in vivo

  • Jul 01, 2019
  • Experimental and Molecular Therapeutics
  • Cathy Chang +9
  • Research Article
  • Citations14

A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.

  • May 20, 2018
  • Journal of Clinical Oncology
  • Jordi Rodon Ahnert +13
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.